179.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$176.98
Aprire:
$177.13
Volume 24 ore:
743.14K
Relative Volume:
0.59
Capitalizzazione di mercato:
$19.39B
Reddito:
$9.54B
Utile/perdita netta:
$841.00M
Rapporto P/E:
24.06
EPS:
7.44
Flusso di cassa netto:
$1.02B
1 W Prestazione:
+3.10%
1M Prestazione:
+1.79%
6M Prestazione:
+14.72%
1 anno Prestazione:
+28.96%
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Confronta DGX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DGX
Quest Diagnostics Inc
|
179.04 | 19.39B | 9.54B | 841.00M | 1.02B | 7.44 |
![]()
TMO
Thermo Fisher Scientific Inc
|
415.33 | 150.38B | 42.90B | 6.52B | 6.72B | 17.05 |
![]()
DHR
Danaher Corp
|
205.10 | 137.52B | 23.82B | 3.77B | 4.90B | 5.15 |
![]()
IDXX
Idexx Laboratories Inc
|
526.92 | 42.00B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
A
Agilent Technologies Inc
|
118.91 | 32.37B | 6.63B | 1.17B | 1.19B | 4.05 |
![]()
IQV
Iqvia Holdings Inc
|
159.13 | 25.50B | 15.50B | 1.33B | 2.16B | 7.34 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-02 | Iniziato | Redburn Atlantic | Buy |
2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | Ripresa | Jefferies | Buy |
2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2024-08-28 | Ripresa | Evercore ISI | In-line |
2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
2024-02-26 | Iniziato | Leerink Partners | Market Perform |
2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
2024-01-03 | Iniziato | Barclays | Equal Weight |
2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
2023-06-29 | Iniziato | Piper Sandler | Neutral |
2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
2023-01-23 | Iniziato | Evercore ISI | In-line |
2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
2022-02-23 | Downgrade | UBS | Buy → Neutral |
2022-02-02 | Downgrade | Jefferies | Buy → Hold |
2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
2020-10-21 | Aggiornamento | Argus | Hold → Buy |
2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-01-08 | Iniziato | Wells Fargo | Underweight |
2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
2019-07-15 | Downgrade | Goldman | Neutral → Sell |
2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
2019-03-18 | Ripresa | Credit Suisse | Neutral |
2019-01-31 | Downgrade | Argus | Buy → Hold |
2019-01-17 | Iniziato | UBS | Neutral |
2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics and University of Texas want to promote more cancer screenings - Mugglehead Magazine
Fecal Immunochemical Diagnostic Test (FIT) Market Top - openPR.com
Quest Diagnostics (DGX) Collaborates with MD Anderson for Cancer Risk Test Development | DGX Stock News - GuruFocus
Quest Diagnostics New Blood Test Could Transform Early Cancer Detection for 9 Major Cancers - Stock Titan
Quest Diagnostics Incorporated : The stock forcefully approaches new pivot levels - marketscreener.com
Quest Diagnostics (DGX) Stock Analysis: Navigating a 5.5% Upside with Strong Revenue Growth - DirectorsTalk Interviews
Transcript : Quest Diagnostics Incorporated Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term - Yahoo Finance
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years - Benzinga
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Participates in Upcoming Oppenheimer Meeting | DGX Stock News - GuruFocus
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick? - The Globe and Mail
Is Wall Street Bullish or Bearish on Quest Diagnostics Stock? - inkl
Is Wall Street Bullish Or Bearish On Quest Diagnostics Stock? - Barchart.com
Quest Diagnostics' $4M Rest Break Settlement Gets Initial OK - Law360
Quest Diagnostics (DGX) Announces Results of 2025 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics Inc (DGX) Shares Gap Down to $171.44 on May 21 - GuruFocus
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year? - Yahoo Finance
Quest Diagnostics stock hits all-time high of $179.37 By Investing.com - Investing.com Nigeria
Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4) - Quantisnow
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference - PR Newswire
Lung Cancer Diagnostics Market Outlook: Opportunities in Early - openPR.com
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Insider Sell: Mark Delaney Sells Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics Keeps Dividend at $0.80 per Share, Payable July 21 to Shareholders as of July 7 - marketscreener.com
Quest Diagnostics (DGX) Declares Consistent Dividend - GuruFocus
Quest Diagnostics Declares Quarterly Cash Dividend - PR Newswire
Quest Diagnostics : Forbes Names Quest Diagnostics One of America's Best Large Employers - marketscreener.com
Is Quest Diagnostics Incorporated's (NYSE:DGX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo
Should You Continue to Retain DGX Stock in Your Portfolio? - TradingView
Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds - Quantisnow
DGX Q1 Earnings Call: Acquisitions, Advanced Diagnostics, and Operational Initiatives Drive Growth - Yahoo Finance
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Quest Diagnostics (DGX) Sees Raised Target Price by JP Morgan | - GuruFocus
Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Quest Diagnostics (DGX) Receives Price Target Increase from JPMo - GuruFocus
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus - MSN
Quest Diagnostics Stock: A Leader But Waiting For Better Price (NYSE:DGX) - Seeking Alpha
Quest Settles Fired Black Phlebotomist's Retaliation Suit - Law360
Bullish on Quest Diagnosis Inc. - The Globe and Mail
This Company Extended Its Post-Earnings Rally to Record Highs - The Globe and Mail
Labcorp beats quarterly profit estimate on diagnostic test demand - Reuters
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook By Investing.com - Investing.com Canada
Fitch elevates Quest Diagnostics’ rating to ’BBB+’ with stable outlook - Investing.com
Piper Sandler Adjusts Price Target on Quest Diagnostics to $200 From $180, Maintains Neutral Rating - marketscreener.com
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight - GuruFocus
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):